Stem definition | Drug id | CAS RN |
---|---|---|
4310 | 175481-36-4 |
Dose | Unit | Route |
---|---|---|
0.30 | g | O |
0.30 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 2 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 40 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 22.83 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.58 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.57 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.85 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 12.30 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 29, 2008 | EMA | ||
Oct. 28, 2008 | FDA | UCB INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Seizure | 2043.84 | 44.42 | 510 | 2148 | 23956 | 2331471 |
Status epilepticus | 1014.40 | 44.42 | 193 | 2465 | 2285 | 2353142 |
Off label use | 690.95 | 44.42 | 295 | 2363 | 73303 | 2282124 |
Generalised tonic-clonic seizure | 592.00 | 44.42 | 142 | 2516 | 5230 | 2350197 |
Epilepsy | 591.44 | 44.42 | 138 | 2520 | 4501 | 2350926 |
Overdose | 423.72 | 44.42 | 146 | 2512 | 19761 | 2335666 |
Drug ineffective | 419.07 | 44.42 | 233 | 2425 | 101391 | 2254036 |
Pregnancy | 355.81 | 44.42 | 103 | 2555 | 7846 | 2347581 |
Partial seizures | 232.17 | 44.42 | 48 | 2610 | 864 | 2354563 |
Dizziness | 208.65 | 44.42 | 123 | 2535 | 58542 | 2296885 |
Diplopia | 191.29 | 44.42 | 53 | 2605 | 3412 | 2352015 |
Somnolence | 178.00 | 44.42 | 82 | 2576 | 23403 | 2332024 |
Focal dyscognitive seizures | 175.64 | 44.42 | 35 | 2623 | 518 | 2354909 |
Maternal exposure during pregnancy | 165.12 | 44.42 | 68 | 2590 | 14795 | 2340632 |
Multiple-drug resistance | 164.10 | 44.42 | 29 | 2629 | 212 | 2355215 |
Bradycardia | 154.20 | 44.42 | 58 | 2600 | 9923 | 2345504 |
Abortion spontaneous | 134.11 | 44.42 | 57 | 2601 | 13388 | 2342039 |
Petit mal epilepsy | 131.92 | 44.42 | 29 | 2629 | 704 | 2354723 |
Tremor | 131.42 | 44.42 | 64 | 2594 | 20597 | 2334830 |
Cardiac arrest | 128.36 | 44.42 | 57 | 2601 | 14873 | 2340554 |
Drug reaction with eosinophilia and systemic symptoms | 126.53 | 44.42 | 43 | 2615 | 5475 | 2349952 |
Depression | 123.75 | 44.42 | 68 | 2590 | 28064 | 2327363 |
Irritability | 120.11 | 44.42 | 43 | 2615 | 6384 | 2349043 |
Premature delivery | 114.61 | 44.42 | 35 | 2623 | 3165 | 2352262 |
Myoclonus | 109.95 | 44.42 | 32 | 2626 | 2451 | 2352976 |
Exposure during pregnancy | 102.75 | 44.42 | 58 | 2600 | 25161 | 2330266 |
Balance disorder | 102.71 | 44.42 | 43 | 2615 | 9704 | 2345723 |
Change in seizure presentation | 101.88 | 44.42 | 15 | 2643 | 25 | 2355402 |
Completed suicide | 101.20 | 44.42 | 54 | 2604 | 20980 | 2334447 |
Fall | 98.41 | 44.42 | 71 | 2587 | 47028 | 2308399 |
Psychotic disorder | 97.66 | 44.42 | 34 | 2624 | 4645 | 2350782 |
Vomiting | 95.89 | 44.42 | 83 | 2575 | 71519 | 2283908 |
Tachycardia | 95.82 | 44.42 | 48 | 2610 | 16361 | 2339066 |
Coma | 92.22 | 44.42 | 39 | 2619 | 9017 | 2346410 |
Aura | 90.75 | 44.42 | 18 | 2640 | 259 | 2355168 |
Intentional overdose | 90.14 | 44.42 | 41 | 2617 | 11280 | 2344147 |
Electrocardiogram QRS complex prolonged | 89.97 | 44.42 | 23 | 2635 | 1079 | 2354348 |
Respiratory acidosis | 86.38 | 44.42 | 21 | 2637 | 800 | 2354627 |
Confusional state | 85.87 | 44.42 | 51 | 2607 | 24293 | 2331134 |
Anxiety | 84.46 | 44.42 | 54 | 2604 | 29305 | 2326122 |
Aphasia | 80.96 | 44.42 | 30 | 2628 | 4898 | 2350529 |
Mitochondrial DNULL mutation | 80.70 | 44.42 | 11 | 2647 | 6 | 2355421 |
Atrioventricular block complete | 79.65 | 44.42 | 22 | 2636 | 1392 | 2354035 |
Encephalopathy | 79.49 | 44.42 | 29 | 2629 | 4532 | 2350895 |
Laryngeal stenosis | 77.26 | 44.42 | 13 | 2645 | 68 | 2355359 |
Abnormal behaviour | 74.62 | 44.42 | 28 | 2630 | 4732 | 2350695 |
Gait disturbance | 73.71 | 44.42 | 45 | 2613 | 22500 | 2332927 |
Atrioventricular block | 73.48 | 44.42 | 20 | 2638 | 1197 | 2354230 |
Sudden unexplained death in epilepsy | 73.41 | 44.42 | 13 | 2645 | 96 | 2355331 |
Disturbance in attention | 73.27 | 44.42 | 29 | 2629 | 5656 | 2349771 |
Memory impairment | 73.04 | 44.42 | 37 | 2621 | 12886 | 2342541 |
Propofol infusion syndrome | 72.83 | 44.42 | 13 | 2645 | 101 | 2355326 |
Drug interaction | 72.55 | 44.42 | 49 | 2609 | 29114 | 2326313 |
Vertigo | 71.58 | 44.42 | 33 | 2625 | 9351 | 2346076 |
Fatigue | 71.04 | 44.42 | 76 | 2582 | 84797 | 2270630 |
Loss of consciousness | 70.56 | 44.42 | 41 | 2617 | 18726 | 2336701 |
Dysarthria | 70.38 | 44.42 | 29 | 2629 | 6273 | 2349154 |
Amnesia | 69.73 | 44.42 | 30 | 2628 | 7223 | 2348204 |
Rash | 69.57 | 44.42 | 64 | 2594 | 59494 | 2295933 |
Weight increased | 66.46 | 44.42 | 42 | 2616 | 22295 | 2333132 |
Electrocardiogram PR prolongation | 63.63 | 44.42 | 12 | 2646 | 130 | 2355297 |
Drug ineffective for unapproved indication | 63.59 | 44.42 | 22 | 2636 | 2944 | 2352483 |
Toxicity to various agents | 62.89 | 44.42 | 47 | 2611 | 32707 | 2322720 |
Headache | 60.44 | 44.42 | 68 | 2590 | 80111 | 2275316 |
Gamma-glutamyltransferase increased | 60.09 | 44.42 | 25 | 2633 | 5537 | 2349890 |
Suicide attempt | 59.96 | 44.42 | 31 | 2627 | 11251 | 2344176 |
Partial seizures with secondary generalisation | 56.56 | 44.42 | 10 | 2648 | 73 | 2355354 |
Metabolic acidosis | 54.99 | 44.42 | 24 | 2634 | 5974 | 2349453 |
Drug resistance | 54.46 | 44.42 | 19 | 2639 | 2605 | 2352822 |
Abortion induced | 53.07 | 44.42 | 20 | 2638 | 3416 | 2352011 |
Condition aggravated | 52.87 | 44.42 | 42 | 2616 | 31937 | 2323490 |
Ataxia | 51.55 | 44.42 | 18 | 2640 | 2474 | 2352953 |
Simple partial seizures | 51.13 | 44.42 | 10 | 2648 | 133 | 2355294 |
Cognitive disorder | 50.86 | 44.42 | 22 | 2636 | 5359 | 2350068 |
Caesarean section | 49.73 | 44.42 | 20 | 2638 | 4061 | 2351366 |
Intentional self-injury | 49.51 | 44.42 | 20 | 2638 | 4107 | 2351320 |
Gene mutation | 48.73 | 44.42 | 10 | 2648 | 172 | 2355255 |
Stillbirth | 48.33 | 44.42 | 15 | 2643 | 1426 | 2354001 |
Ventricular tachycardia | 48.22 | 44.42 | 18 | 2640 | 2993 | 2352434 |
Lipids abnormal | 48.11 | 44.42 | 9 | 2649 | 93 | 2355334 |
Seizure cluster | 47.84 | 44.42 | 8 | 2650 | 40 | 2355387 |
Electroencephalogram abnormal | 47.17 | 44.42 | 13 | 2645 | 814 | 2354613 |
Hyponatraemia | 47.12 | 44.42 | 28 | 2630 | 13297 | 2342130 |
Nausea | 46.68 | 44.42 | 71 | 2587 | 112118 | 2243309 |
Head injury | 46.51 | 44.42 | 19 | 2639 | 4015 | 2351412 |
Suicidal ideation | 46.40 | 44.42 | 26 | 2632 | 11061 | 2344366 |
Myoclonic epilepsy | 46.05 | 44.42 | 10 | 2648 | 228 | 2355199 |
Ventricular fibrillation | 45.91 | 44.42 | 16 | 2642 | 2185 | 2353242 |
Arrhythmia | 45.32 | 44.42 | 21 | 2637 | 6007 | 2349420 |
Atrioventricular block second degree | 44.97 | 44.42 | 12 | 2646 | 665 | 2354762 |
Death | 44.87 | 44.42 | 59 | 2599 | 81409 | 2274018 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Seizure | 1751.05 | 38.75 | 463 | 1751 | 19978 | 1724589 |
Status epilepticus | 649.09 | 38.75 | 136 | 2078 | 1910 | 1742657 |
Off label use | 586.13 | 38.75 | 239 | 1975 | 38332 | 1706235 |
Generalised tonic-clonic seizure | 516.06 | 38.75 | 128 | 2086 | 3918 | 1740649 |
Epilepsy | 385.00 | 38.75 | 101 | 2113 | 3858 | 1740709 |
Drug ineffective | 270.26 | 38.75 | 167 | 2047 | 63634 | 1680933 |
Overdose | 238.84 | 38.75 | 100 | 2114 | 16601 | 1727966 |
Partial seizures | 228.86 | 38.75 | 48 | 2166 | 663 | 1743904 |
Foetal exposure during pregnancy | 154.20 | 38.75 | 56 | 2158 | 6303 | 1738264 |
Focal dyscognitive seizures | 151.82 | 38.75 | 30 | 2184 | 300 | 1744267 |
Aggression | 151.48 | 38.75 | 59 | 2155 | 8056 | 1736511 |
Sudden unexplained death in epilepsy | 150.85 | 38.75 | 26 | 2188 | 110 | 1744457 |
Somnolence | 142.65 | 38.75 | 70 | 2144 | 16669 | 1727898 |
Dizziness | 136.75 | 38.75 | 87 | 2127 | 34274 | 1710293 |
Bradycardia | 107.72 | 38.75 | 50 | 2164 | 10484 | 1734083 |
Fall | 95.99 | 38.75 | 64 | 2150 | 27150 | 1717417 |
Toxicity to various agents | 87.33 | 38.75 | 62 | 2152 | 29079 | 1715488 |
Multiple-drug resistance | 83.00 | 38.75 | 18 | 2196 | 292 | 1744275 |
Atrioventricular block | 82.12 | 38.75 | 24 | 2190 | 1347 | 1743220 |
Agitation | 81.63 | 38.75 | 42 | 2172 | 10984 | 1733583 |
Drug resistance | 80.23 | 38.75 | 29 | 2185 | 3201 | 1741366 |
Cardiac arrest | 77.51 | 38.75 | 46 | 2168 | 15884 | 1728683 |
Atrioventricular block complete | 76.13 | 38.75 | 23 | 2191 | 1448 | 1743119 |
Ataxia | 73.26 | 38.75 | 25 | 2189 | 2328 | 1742239 |
Premature baby | 71.51 | 38.75 | 26 | 2188 | 2916 | 1741651 |
Maternal exposure during pregnancy | 67.91 | 38.75 | 18 | 2196 | 702 | 1743865 |
Encephalopathy | 67.77 | 38.75 | 28 | 2186 | 4424 | 1740143 |
Confusional state | 65.32 | 38.75 | 46 | 2168 | 21232 | 1723335 |
Atrioventricular block second degree | 65.32 | 38.75 | 17 | 2197 | 617 | 1743950 |
Atrial septal defect | 65.00 | 38.75 | 20 | 2194 | 1338 | 1743229 |
Petit mal epilepsy | 62.26 | 38.75 | 16 | 2198 | 552 | 1744015 |
Vomiting | 62.26 | 38.75 | 57 | 2157 | 38258 | 1706309 |
Aura | 61.72 | 38.75 | 12 | 2202 | 109 | 1744458 |
Congenital hypoplasia of depressor angularis oris muscle | 59.61 | 38.75 | 8 | 2206 | 0 | 1744567 |
Hepatocellular injury | 58.40 | 38.75 | 23 | 2191 | 3208 | 1741359 |
Diplopia | 56.13 | 38.75 | 21 | 2193 | 2549 | 1742018 |
Cognitive disorder | 55.14 | 38.75 | 24 | 2190 | 4306 | 1740261 |
Gait disturbance | 54.91 | 38.75 | 34 | 2180 | 12636 | 1731931 |
Suicide attempt | 54.23 | 38.75 | 28 | 2186 | 7353 | 1737214 |
Balance disorder | 51.38 | 38.75 | 25 | 2189 | 5787 | 1738780 |
Acoustic stimulation tests abnormal | 49.31 | 38.75 | 8 | 2206 | 21 | 1744546 |
Syncope | 49.01 | 38.75 | 33 | 2181 | 14136 | 1730431 |
Cholestasis | 48.91 | 38.75 | 21 | 2193 | 3644 | 1740923 |
Partial seizures with secondary generalisation | 48.88 | 38.75 | 9 | 2205 | 59 | 1744508 |
Suicidal ideation | 47.74 | 38.75 | 27 | 2187 | 8491 | 1736076 |
Atrial fibrillation | 47.08 | 38.75 | 33 | 2181 | 15078 | 1729489 |
Unmasking of previously unidentified disease | 46.56 | 38.75 | 9 | 2205 | 79 | 1744488 |
Low birth weight baby | 46.44 | 38.75 | 14 | 2200 | 873 | 1743694 |
Depression | 46.43 | 38.75 | 34 | 2180 | 16635 | 1727932 |
Delirium | 46.34 | 38.75 | 24 | 2190 | 6338 | 1738229 |
Head injury | 45.93 | 38.75 | 19 | 2195 | 3005 | 1741562 |
Inappropriate schedule of product administration | 45.50 | 38.75 | 25 | 2189 | 7434 | 1737133 |
Loss of consciousness | 45.22 | 38.75 | 32 | 2182 | 14843 | 1729724 |
Tremor | 44.01 | 38.75 | 30 | 2184 | 13101 | 1731466 |
Drug ineffective for unapproved indication | 43.81 | 38.75 | 16 | 2198 | 1813 | 1742754 |
Abnormal behaviour | 43.55 | 38.75 | 23 | 2191 | 6319 | 1738248 |
Hippocampal sclerosis | 43.54 | 38.75 | 7 | 2207 | 17 | 1744550 |
Amnesia | 43.11 | 38.75 | 21 | 2193 | 4870 | 1739697 |
Psychotic disorder | 42.45 | 38.75 | 21 | 2193 | 5035 | 1739532 |
Drug interaction | 42.24 | 38.75 | 40 | 2174 | 27918 | 1716649 |
Exposure via breast milk | 41.76 | 38.75 | 10 | 2204 | 256 | 1744311 |
Pneumonia aspiration | 41.64 | 38.75 | 21 | 2193 | 5245 | 1739322 |
Anomaly of external ear congenital | 41.51 | 38.75 | 8 | 2206 | 69 | 1744498 |
Coarctation of the aorta | 41.48 | 38.75 | 9 | 2205 | 146 | 1744421 |
Condition aggravated | 41.32 | 38.75 | 35 | 2179 | 21115 | 1723452 |
Postictal psychosis | 41.31 | 38.75 | 7 | 2207 | 26 | 1744541 |
Mydriasis | 40.93 | 38.75 | 14 | 2200 | 1310 | 1743257 |
Hyperammonaemia | 39.68 | 38.75 | 13 | 2201 | 1065 | 1743502 |
Source | Code | Description |
---|---|---|
ATC | N03AX18 | NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics |
FDA EPC | N0000175753 | Anti-epileptic Agent |
FDA PE | N0000008486 | Decreased Central Nervous System Disorganized Electrical Activity |
MeSH PA | D000927 | Anticonvulsants |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D026941 | Sodium Channel Blockers |
MeSH PA | D061567 | Voltage-Gated Sodium Channel Blockers |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Partial Epilepsy Treatment Adjunct | indication | ||
Atrial flutter | contraindication | 5370000 | |
Suicidal thoughts | contraindication | 6471006 | |
Complete atrioventricular block | contraindication | 27885002 | |
Orthostatic hypotension | contraindication | 28651003 | |
Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
Chronic heart failure | contraindication | 48447003 | |
Atrial fibrillation | contraindication | 49436004 | DOID:0060224 |
Acute nephropathy | contraindication | 58574008 | |
Second degree atrioventricular block | contraindication | 195042002 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Suicidal | contraindication | 267073005 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Severe Cardiac Disease | contraindication | ||
First Degree Atrioventricular Heart Block | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.83 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
100MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER |
100MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
150MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER |
150MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
200MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER |
200MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
50MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER |
50MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
200MG/20ML (10MG/ML) | VIMPAT | UCB INC | N022254 | Oct. 28, 2008 | RX | SOLUTION | INTRAVENOUS | RE38551 | March 17, 2022 | METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE |
200MG/20ML (10MG/ML) | VIMPAT | UCB INC | N022254 | Oct. 28, 2008 | RX | SOLUTION | INTRAVENOUS | RE38551 | March 17, 2022 | METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE |
10MG/ML | VIMPAT | UCB INC | N022255 | April 20, 2010 | RX | SOLUTION | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER |
10MG/ML | VIMPAT | UCB INC | N022255 | April 20, 2010 | RX | SOLUTION | ORAL | RE38551 | March 17, 2022 | METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
100MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | Nov. 3, 2020 | NEW PATIENT POPULATION |
150MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | Nov. 3, 2020 | NEW PATIENT POPULATION |
200MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | Nov. 3, 2020 | NEW PATIENT POPULATION |
50MG | VIMPAT | UCB INC | N022253 | Oct. 28, 2008 | RX | TABLET | ORAL | Nov. 3, 2020 | NEW PATIENT POPULATION |
200MG/20ML (10MG/ML) | VIMPAT | UCB INC | N022254 | Oct. 28, 2008 | RX | SOLUTION | INTRAVENOUS | Nov. 3, 2020 | INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING |
10MG/ML | VIMPAT | UCB INC | N022255 | April 20, 2010 | RX | SOLUTION | ORAL | Nov. 3, 2020 | NEW PATIENT POPULATION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium channel protein type 9 subunit alpha | Ion channel | BLOCKER | IC50 | 6.74 | CHEMBL | CHEMBL | |||
Carbonic anhydrase 2 | Enzyme | Ki | 6.48 | CHEMBL | |||||
Carbonic anhydrase 12 | Enzyme | Ki | 5.43 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 6.28 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 5.92 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 6.43 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 5.34 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 6.33 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 5.35 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 6.45 | CHEMBL | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 6.44 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 6.47 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 6.39 | CHEMBL | |||||
Dihydropyrimidinase-related protein 2 | Unclassified | WOMBAT-PK | |||||||
Sodium channel protein type X alpha subunit | Unclassified | IC50 | 4.80 | CHEMBL | |||||
Sodium channel protein type 3 subunit alpha | Ion channel | IC50 | 6.38 | CHEMBL | |||||
Carbonic anhydrase 15 | Enzyme | Ki | 6.34 | CHEMBL | |||||
Sodium channel protein type 2 subunit alpha | Ion channel | BLOCKER | IC50 | 4.52 | IUPHAR |
ID | Source |
---|---|
D000078334 | MESH_DESCRIPTOR_UI |
4028103 | VUID |
N0000179735 | NUI |
C0893761 | UMLSCUI |
D07299 | KEGG_DRUG |
563KS2PQY5 | UNII |
8094 | INN_ID |
441532003 | SNOMEDCT_US |
623400 | RXNORM |
25914 | MMSL |
d07349 | MMSL |
4028103 | VANDF |
441647003 | SNOMEDCT_US |
012839 | NDDF |
CHEMBL58323 | ChEMBL_ID |
C476828 | MESH_SUPPLEMENTAL_RECORD_UI |
DB06218 | DRUGBANK_ID |
CHEBI:135939 | CHEBI |
219078 | PUBCHEM_CID |
7472 | IUPHAR_LIGAND_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0131-1810 | INJECTION | 10 mg | INTRAVENOUS | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0131-2470 | KIT | 50 mg | None | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0131-2470 | KIT | 100 mg | None | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0131-2477 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0131-2478 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0131-2479 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0131-2480 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0131-5410 | SOLUTION | 10 mg | ORAL | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6077 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 18 sections |
Lacosamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63850-0053 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 18 sections |
Lacosamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63850-0054 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 18 sections |
Lacosamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63850-0055 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 18 sections |
Lacosamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63850-0056 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 18 sections |
Lacosamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-912 | SOLUTION | 10 mg | ORAL | ANDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70166-617 | SOLUTION | 10 mg | ORAL | NDA | 19 sections |
Vimpat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-0257 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 19 sections |